SECOND REGULAR SESSION
HOUSE BILL NO. 2262
102ND GENERAL ASSEMBLY
INTRODUCED BY REPRESENTATIVE NURRENBERN.
4805H.01I DANARADEMANMILLER,ChiefClerk
AN ACT
To amend chapter 376, RSMo, by adding thereto one new section relating to insurance
coverage for prescription insulin drugs.
Be it enacted by the General Assembly of the state of Missouri, as follows:
Section A. Chapter 376, RSMo, is amended by adding thereto one new section, to be
2 known as section 376.389, to read as follows:
376.389. 1. As used in this section, the following terms shall mean:
2 (1) "Cost-sharing", expenses imposed on an enrollee for a covered health care
3 serviceundertheenrollee'shealthbenefitplanincluding,butnotlimitedto,deductibles,
4 co-payments, and coinsurance;
5 (2) "Drug", the same meaning as is ascribed to such term in section 376.1350;
6 (3) "Enrollee",thesamemeaningasisascribedtosuchterminsection376.1350;
7 (4) "Health benefit plan", the same meaning as is ascribed to such term in
8 section 376.1350;
9 (5) "Health care service", the same meaning as is ascribed to such term in
10 section 376.1350;
11 (6) "Health carrier", the same meaning as is ascribed to such term in section
12 376.1350;
13 (7) "Pharmacy", the same meaning as is ascribed to such term in section
14 338.210;
15 (8) "Prescription insulin drug", a drug that contains insulin and is used to
16 control blood glucose levels to treat diabetes, except that such term shall not include an
17 insulin drug that is administered to a patient intravenously;
EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is
intended to be omitted from the law. Matter in bold-face type in the above bill is proposed language.
HB 2262 2
18 (9) "Rebate", any discount, negotiated concession, or other payment provided
19 by a pharmaceutical manufacturer, pharmacy, or health benefit plan to an entity to sell,
20 provide, pay, or reimburse a pharmacy or other entity in the state for the dispensing or
21 administration of drugs on behalf of itself or another entity;
22 (10) "Trade secret", the same meaning as is ascribed to such term in section
23 417.453.
24 2. No health benefit plan that provides coverage for prescription insulin drugs
25 shall impose cost-sharing on an enrollee in excess of thirty dollars per thirty-day supply
26 of a prescription insulin drug.
27 3. (1) An enrollee's cost-sharing for prescription insulin drugs shall be
28 calculated at the point of sale based on a drug price that is reduced by an amount equal
29 to at least one hundred percent of all rebates received, or to be received, in connection
30 with the dispensing or administration of the drug.
31 (2) Nothing in this subsection shall prohibit a co-payment not calculated based
32 on drug price, provided that the co-payment does not exceed the reduced price of the
33 drug.
34 (3) Nothing in this subsection shall preclude a health carrier from reducing a
35 covered individual's cost-sharing for a prescription insulin drug by an amount greater
36 than that required under this subsection.
37 (4) In complying with the provisions of this subsection, no health carrier or its
38 agents shall be required to publish or otherwise reveal information regarding the actual
39 amount of rebates a health carrier receives on a product, manufacturer, or pharmacy-
40 specificbasis. Suchinformationshallbeprotectedasatradesecret,shallnotbeapublic
41 record under chapter 610, and shall not be disclosed directly or indirectly. A health
42 carriershallimposetheconfidentialityprotectionsofthissectiononanyvendororother
43 third party that performs health care or administrative services on behalf of the health
44 carrier and that may receive or have access to rebate information.
45 4. If any provision of this section or the application thereof to anyone or to any
46 circumstance is held invalid, the remainder of this section and the application of such
47 provisions to others or other circumstances shall not be affected thereby.
48 5. This section shall apply to health benefit plans delivered, issued for delivery,
49 continued, or renewed on or after January 1, 2025.
✔